Screener
Halozyme Therapeutics HALO Proceeds From Previous Acquisition
Proceeds From Previous Acquisition at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromPreviousAcquisition.
The source filing: Halozyme Therapeutics’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001159036-26-000068
| Line item | Three Months Ended / March 31, 2026 | Three Months Ended / March 31, 2025 |
|---|---|---|
| Investing activities | ||
| Purchases of marketable securities | (8,846) | (139,639) |
| Proceeds from sales and maturities of marketable securities | 9,000 | 50,167 |
| Proceeds from working capital adjustments on acquisition | 710 | — |
| Purchases of property and equipment | (3,741) | (950) |
| Net cash used in investing activities | (2,877) | (90,422) |
| Financing activities | ||
| Taxes paid related to net share settlement, net of proceeds from issuance of common stock under equity incentive plans | (1,613) | (3,321) |
Item 1. Financial Statements
FAQ
- What is Halozyme Therapeutics's proceeds from previous acquisition?
- Halozyme Therapeutics (HALO) reported proceeds from previous acquisition of $710K in Q1 2026.
- What does proceeds from previous acquisition mean?
- Proceeds From Previous Acquisition
Ask your AI about Halozyme Therapeutics's proceeds from previous acquisition.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude